[go: up one dir, main page]

PE20130379A1 - Metodos para el tratamiento de las ulceras del pie diabetico - Google Patents

Metodos para el tratamiento de las ulceras del pie diabetico

Info

Publication number
PE20130379A1
PE20130379A1 PE2012001812A PE2012001812A PE20130379A1 PE 20130379 A1 PE20130379 A1 PE 20130379A1 PE 2012001812 A PE2012001812 A PE 2012001812A PE 2012001812 A PE2012001812 A PE 2012001812A PE 20130379 A1 PE20130379 A1 PE 20130379A1
Authority
PE
Peru
Prior art keywords
weight
treatment
diabetic foot
foot ulcers
methods
Prior art date
Application number
PE2012001812A
Other languages
English (en)
Inventor
Kathleen E Rodgers
Gere S Dizerega
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45571822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130379(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Southern California filed Critical Univ Southern California
Publication of PE20130379A1 publication Critical patent/PE20130379A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/085Angiotensins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA QUE COMPRENDE (a) 0.5% A APROXIMADAMENTE 4% DE HIDROXIETILCELULOSA (HEC) SOBRE UNA BASE DE PESO (MG)/VOLUMEN (ML), O SOBRE UNA BASE DE PESO/ PESO (MG); (b) UN PEPTIDO DE POR LO MENOS 5 AMINOACIDOS CONTIGUOS TAL COMO ASP-ARG-NLE-TYR-ILE-HIS-PRO (SEQ ID NO:1),CON UNA CONCENTRACION DE 0.03% A APROXIMADAMENTE 1% SOBRE UNA BASE DE PESO (MG)/VOLUMEN (ML) O SOBRE UNA BASE DE PESO/PESO (MG). DICHA FORMULACION ES UN HIDROGEL, UTIL EN EL TRATAMIENTO DE ULCERAS DE PIE DIABETICO.
PE2012001812A 2011-02-02 2012-02-01 Metodos para el tratamiento de las ulceras del pie diabetico PE20130379A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161438780P 2011-02-02 2011-02-02

Publications (1)

Publication Number Publication Date
PE20130379A1 true PE20130379A1 (es) 2013-04-13

Family

ID=45571822

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012001812A PE20130379A1 (es) 2011-02-02 2012-02-01 Metodos para el tratamiento de las ulceras del pie diabetico

Country Status (20)

Country Link
US (3) US8207233B1 (es)
EP (1) EP2536422B8 (es)
JP (2) JP5469777B2 (es)
KR (1) KR101514414B1 (es)
CN (1) CN102858360B (es)
AU (1) AU2012212220B2 (es)
BR (1) BR112013019513A2 (es)
CA (1) CA2793515C (es)
CL (1) CL2012002560A1 (es)
CO (1) CO6592101A2 (es)
DK (1) DK2536422T3 (es)
EA (1) EA026440B1 (es)
ES (1) ES2479765T3 (es)
MX (1) MX2012010783A (es)
PE (1) PE20130379A1 (es)
PL (1) PL2536422T3 (es)
PT (1) PT2536422E (es)
SG (1) SG183960A1 (es)
WO (1) WO2012106427A2 (es)
ZA (1) ZA201207340B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2536422T3 (da) * 2011-02-02 2014-07-28 Univ Southern California Fremgangsmåder til behandling af diabetiske fodsår
WO2013172956A1 (en) 2012-05-14 2013-11-21 University Of Southern California Methods for limiting development of a skin wound
EP2895154A4 (en) * 2012-09-17 2016-04-20 Tarix Pharmaceuticals Ltd ORAL FORMULATIONS OF ANGIOTENSIN
US9289500B2 (en) * 2013-02-22 2016-03-22 The Regents Of The University Of California Saccharide-peptide hydrogels
CA2911376C (en) 2013-03-15 2021-03-30 University Of Southern California Phenyl(sulfonylcarbamate) derivatives and pharmaceutical compositions thereof for the treatment of angiotensin-related diseases
US9623084B2 (en) 2013-03-15 2017-04-18 University Of Southern California Methods for treating multiple sclerosis
WO2015138288A1 (en) * 2014-03-10 2015-09-17 Rush University Medical Center Methods of promotion of healing of diabetic wounds
WO2016108130A1 (en) * 2014-12-30 2016-07-07 Sun Pharmaceutical Industries Limited Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds
US20180344680A1 (en) * 2015-12-08 2018-12-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers
WO2021072225A1 (en) * 2019-10-09 2021-04-15 Rush University Medical Center Modulating interleukin-10 signaling to boost healing in diabetic wounds

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015629A (en) 1989-06-26 1991-05-14 University Of Southern California Tissue repair
WO1993008825A1 (en) * 1991-11-04 1993-05-13 Zymogenetics, Inc. Pdgf gel formulation
WO1995008337A1 (en) 1993-09-24 1995-03-30 The University Of Southern California Use of angiotensin iii and analogs thereof in tissue repair
US5955430A (en) 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
ATE473995T1 (de) 1993-09-24 2010-07-15 Univ Southern California Verwendung von angiotensin-ii-analogen zur gewebewiederherstellung
US5834432A (en) 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
US6110895A (en) 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
US6335195B1 (en) 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
WO1998033813A2 (en) 1997-02-04 1998-08-06 University Of Southern California Method for accelerating healing of thermal injuries
US6248587B1 (en) 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
US6165978A (en) 1997-12-12 2000-12-26 University Of Southern California Wound healing composition
EP1053005A2 (en) 1998-02-09 2000-11-22 University Of Southern California Method of promoting keratinocyte proliferation
US7173011B2 (en) 2000-11-20 2007-02-06 University Of Southern California Radiation therapy methods
US6455500B1 (en) 1998-03-10 2002-09-24 University Of Southern California Radiation therapy methods
US6498138B1 (en) 1998-03-11 2002-12-24 University Of Southern California Method of promoting production of living tissue equivalents
US6475988B1 (en) 1998-05-11 2002-11-05 University Of Southern California Methods to increase white blood cell survival after chemotherapy
US6762167B1 (en) 1998-05-11 2004-07-13 University Of Southern California Methods for treating a patient undergoing chemotherapy
US6916783B2 (en) 1998-07-13 2005-07-12 University Of Southern California Methods for accelerating bone and cartilage growth and repair
CA2328871C (en) 1998-07-13 2002-10-01 University Of Southern California Methods for accelerating bone and cartilage growth and repair
JP2002522505A (ja) 1998-08-13 2002-07-23 ユニヴァースティ オブ サザーン カリフォルニア 虚血組織への血流を増加させる方法
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
US7338938B2 (en) 1999-05-10 2008-03-04 University Of Southern California Methods for treating a patient undergoing chemotherapy
AU1792901A (en) 1999-12-16 2001-06-25 University Of Southern California Methods for treating and preventing diabetic complications
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
EP1292610A1 (en) * 2000-06-19 2003-03-19 University Of Southern California Methods for treating and preventing alopecia
US20060058238A1 (en) 2004-09-15 2006-03-16 Lee Laurent-Applegate Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
CA2709151A1 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20090227507A1 (en) 2008-03-10 2009-09-10 University Of Southern California Angiotensin (1-7) Dosage Forms and Uses Thereof
SG184247A1 (en) 2010-03-26 2012-10-30 Univ Southern California Methods for treating combined radiation and thermal injury
EP2603228A1 (en) 2010-08-10 2013-06-19 The University Of Southern California Use of angiotensin- ii (1-7) in cell transplantation and as an agent for preventing/treating norovirus infection
DK2536422T3 (da) * 2011-02-02 2014-07-28 Univ Southern California Fremgangsmåder til behandling af diabetiske fodsår

Also Published As

Publication number Publication date
WO2012106427A3 (en) 2012-09-20
EP2536422A2 (en) 2012-12-26
EP2536422B8 (en) 2023-06-21
US8207233B1 (en) 2012-06-26
ES2479765T3 (es) 2014-07-24
BR112013019513A2 (pt) 2019-06-11
CA2793515A1 (en) 2012-08-09
JP5469777B2 (ja) 2014-04-16
CL2012002560A1 (es) 2013-03-22
WO2012106427A2 (en) 2012-08-09
US20120329729A1 (en) 2012-12-27
SG183960A1 (en) 2012-10-30
CN102858360B (zh) 2017-07-25
CO6592101A2 (es) 2013-01-02
JP2013523781A (ja) 2013-06-17
KR101514414B1 (ko) 2015-05-04
ZA201207340B (en) 2013-02-27
US8207234B1 (en) 2012-06-26
CN102858360A (zh) 2013-01-02
EP2536422B1 (en) 2014-04-30
AU2012212220B2 (en) 2013-04-04
HK1180213A1 (en) 2013-10-18
US8536231B2 (en) 2013-09-17
EA026440B1 (ru) 2017-04-28
MX2012010783A (es) 2012-11-23
JP2014080425A (ja) 2014-05-08
PT2536422E (pt) 2014-07-18
EA201201296A1 (ru) 2013-02-28
KR20120137365A (ko) 2012-12-20
DK2536422T3 (da) 2014-07-28
CA2793515C (en) 2015-05-12
AU2012212220A1 (en) 2012-10-18
PL2536422T3 (pl) 2014-09-30

Similar Documents

Publication Publication Date Title
PE20130379A1 (es) Metodos para el tratamiento de las ulceras del pie diabetico
NI201200013A (es) Composición de insulina de acción prolongada
CO6382125A2 (es) Inhibidores de proteína quinasa
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
CL2009001340A1 (es) Compuesto de insulina lispro pegilada o una sal del mismo que comprende una cadena a de sec no:1, una cadena b de sec no:3 y el peg es de un peso entre 20 a 40 kda; uso de dicho compuesto para tratar hipoglicemia o diabetes; composición farmacéutica que comprende dicho compuesto; y proceso para elaborar dicho compuesto.
EA201590058A1 (ru) Аналоги глюкагона
PA8811601A1 (es) Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado
MY156188A (en) Long - acting formulations of insulins
AR092925A1 (es) Derivados de exendina-4 como agonistas duales de glp1 / glucagon
AR083162A1 (es) Uso de ingredientes activos para controlar nematodos en cultivos resistentes a nematodos
AR091422A1 (es) Analogos peptidicos de la exendina 4
MX2016001971A (es) Composiciones farmaceuticas parenterales acuosas estables de peptidos insulinotropicos.
EA201370178A1 (ru) Стабильные составы для парентеральной инъекции пептидных лекарственных средств
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
NI201200017A (es) Formulación farmacéutica
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
PH12015501931B1 (en) Treatment of diabetes mellitus by long-acting formulations of insulins
ES2673406T3 (es) Alfa-derivados de ácidos grasos cis-monoinsaturados para uso como medicamentos en el tratamiento de la diabetes
NI201000173A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre.
AR075041A1 (es) Composicion farmaceutica que contiene aleglitazar, proceso, uso.
CL2009001006A1 (es) Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras.
EA201490041A1 (ru) Пластырь, содержащий диклофенак и тиоколхикозид
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
DOP2010000156A (es) Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca

Legal Events

Date Code Title Description
FC Refusal